Christopher Richard Anzalone, Chief Executive Officer at ARROWHEAD PHARMACEUTICALS, INC. (ARWR), sold 48,676 shares at $24.21 ($1.2M) on 2023-10-25, disclosed to the SEC on 2023-10-27.
Scheduled sale ($1.2M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $24.21 | 24,338 | $589K | 50.0% |
| 2 | $24.21 | 24,338 | $589K | 50.0% |
| Total | $24.21 avg | 48,676 | $1.2M | 100% |
| Filing → |
| ARWR | SELL | 2025-12-23 | $3.5M | — | Filing → |
| ARWR | SELL | 2025-12-19 | $10.9M | — | Filing → |
| ARWR | SELL | 2025-12-16 | $24.6M | — | Filing → |